Tri Locum Partners LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001826434
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 24 positions · Total reported value $218.76M · Top-10 concentration 66.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 90.9% · 3 new · 13 cut · 4 exited
Active Share (vs S&P 500): 97.4% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -1.6% · vs SPY -3.7% · Prev Value $813.22M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +2.1% · vs SPY -0.0% · Latest Value $506.14M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2023 13F filing, Tri Locum Partners LP disclosed 24 equity positions with a combined reported value of $218.76M. The filing implies a focused portfolio: its ten largest positions account for 66.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were ABBV ($26.01M), TEVA ($18.73M), KVUE ($15.05M). By sector, the heaviest allocations are Health Care 77.8%, Consumer Discretionary 6.9%. Versus the prior quarter, allocation shifted toward Consumer Discretionary (+6.3pp), Health Care (+4.9pp) and away from Other (-10.7pp).
Versus the prior quarter, Tri Locum Partners LP opened 3 new positions, trimmed 13 and fully exited 4, a turnover rate of 90.9% of positions. The portfolio's overlap with the prior quarter was 31% of names.
The largest new positions opened in Q4 2023 were ASND ($12.54M), BIIB ($11.86M), LEGN ($6.15M).
Of the 4 positions fully exited versus the prior quarter, the largest were AMGN ($28.89M), DXCM ($24.95M), SPY ($19.33M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- ASND ASCENDIS PHARMA A/S · $12.54M
- BIIB BIOGEN INC · $11.86M
- LEGN LEGEND BIOTECH CORP · $6.15M
- SRRK SCHOLAR ROCK HLDG CORP · $3.89M
Fully Exited (vs previous quarter)
- AMGN AMGEN INC · prev qtr: $28.89M
- DXCM DEXCOM INC · prev qtr: $24.95M · history
- SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $19.33M
- WST WEST PHARMACEUTICAL SVSC INC · prev qtr: $8.42M
- SILK SILK RD MED INC · prev qtr: $8.04M
- XFOR X4 PHARMACEUTICALS INC · prev qtr: $6.81M
- IMGN IMMUNOGEN INC · prev qtr: $5.87M
- NUVL NUVALENT INC · prev qtr: $5.22M
Insider Transactions (Form 4)
Latest Tri Locum Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Tri Locum Partners LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 19 positions worth $813.22M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-119074 (status: Approved), registered 2020-07-16
- Regulatory AUM (Form ADV): $1.09B as of 2026-04-06
- Client mix (by RAUM): pension and profit-sharing plans 64%, sovereign wealth funds 36%
- Manages 1 private funds, of which 1 hedge funds
Portfolio Structure
- 19 positions · $813.22M reported value (Q2 2026)
- Top 10 holdings = 80.0% of reported value
- Largest position: JNJ (JOHNSON & JOHNSON) at 13.3%
- Average position size: $42.80M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 4 new, 9 added, 6 reduced, 2 exited
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
167.81K | $26.01M | 11.89% | Add | |
| 2 |
|
1.79M | $18.73M | 8.56% | Reduce | |
| 3 |
|
698.80K | $15.05M | 6.88% | Add | |
| 4 |
|
16.01K | $14.06M | 6.43% | Reduce | |
| 5 |
|
171.68K | $13.27M | 6.07% | Add | |
| 6 |
|
99.55K | $12.54M | 5.73% | New | |
| 7 |
|
839.93K | $11.86M | 5.42% | Reduce | |
| 8 |
|
45.81K | $11.86M | 5.42% | New | |
| 9 |
|
261.80K | $11.76M | 5.38% | Reduce | |
| 10 |
|
130.74K | $10.41M | 4.76% | Reduce | |
| 11 |
|
225.56K | $10.39M | 4.75% | Add | |
| 12 |
|
24.18K | $9.20M | 4.21% | Add | |
| 13 |
|
141.85K | $8.89M | 4.06% | Reduce | |
| 14 |
|
102.22K | $6.15M | 2.81% | New | |
| 15 |
|
25.52K | $5.91M | 2.70% | Reduce | |
| 16 |
|
293.11K | $5.83M | 2.66% | Reduce | |
| 17 |
|
248.76K | $5.54M | 2.53% | Reduce | |
| 18 |
|
542.95K | $4.17M | 1.91% | Reduce | |
| 19 |
|
58.79K | $3.96M | 1.81% | Add | |
| 20 |
|
207.15K | $3.89M | 1.78% | New | |
| 21 |
|
110.47K | $3.48M | 1.59% | Reduce | |
| 22 |
|
275.48K | $2.90M | 1.33% | Reduce | |
| 23 |
|
47.60K | $2.87M | 1.31% | Reduce | |
| 24 |
|
36.15K | $35.25K | 0.02% | Reduce | |
FAQ
What did Tri Locum Partners LP buy in 2023-Q4?
In its 2023-Q4 13F filing, Tri Locum Partners LP reported 24 equity positions worth $218.76M in aggregate; its largest disclosed positions were ABBV ($26.01M), TEVA ($18.73M), KVUE ($15.05M).
How large is Tri Locum Partners LP's portfolio?
Tri Locum Partners LP reported $218.76M of long equity holdings across 24 positions as of 2023-Q4. Top-10 holdings account for 66.5% of reported value.
What is Tri Locum Partners LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.